JP2025503109A5 - - Google Patents
Info
- Publication number
- JP2025503109A5 JP2025503109A5 JP2024543463A JP2024543463A JP2025503109A5 JP 2025503109 A5 JP2025503109 A5 JP 2025503109A5 JP 2024543463 A JP2024543463 A JP 2024543463A JP 2024543463 A JP2024543463 A JP 2024543463A JP 2025503109 A5 JP2025503109 A5 JP 2025503109A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tumor
- antigen
- associated antigen
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302514P | 2022-01-24 | 2022-01-24 | |
| US63/302,514 | 2022-01-24 | ||
| PCT/EP2023/051721 WO2023139293A1 (en) | 2022-01-24 | 2023-01-24 | Composition and methods for the selective activation of cytokine signaling pathways |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503109A JP2025503109A (ja) | 2025-01-30 |
| JP2025503109A5 true JP2025503109A5 (enExample) | 2026-01-22 |
Family
ID=85278300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543463A Pending JP2025503109A (ja) | 2022-01-24 | 2023-01-24 | サイトカインシグナル伝達経路の選択的な活性化のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230295348A1 (enExample) |
| EP (1) | EP4469163A1 (enExample) |
| JP (1) | JP2025503109A (enExample) |
| CN (1) | CN118715024A (enExample) |
| AU (1) | AU2023208426A1 (enExample) |
| CA (1) | CA3248133A1 (enExample) |
| IL (1) | IL314068A (enExample) |
| WO (1) | WO2023139293A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL305828A (en) * | 2021-03-22 | 2023-11-01 | Novimmune Sa | Bispecific antibodies targeting CD47 and PD-L1 and methods of using them |
| EP4493592A1 (en) | 2022-03-14 | 2025-01-22 | LamKap Bio gamma AG | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| WO2026039791A1 (en) * | 2024-08-16 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il2 receptor agonists |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| CN108290958B (zh) | 2015-10-02 | 2021-12-28 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| GB201700345D0 (en) * | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| US11260117B2 (en) | 2017-05-26 | 2022-03-01 | Novimmune Sa | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof |
| JP2022511390A (ja) * | 2018-11-20 | 2022-01-31 | ユニバーシティ オブ ワシントン | 分割インターロイキン模倣体およびその使用 |
| EP3897851A2 (en) * | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
-
2023
- 2023-01-24 AU AU2023208426A patent/AU2023208426A1/en active Pending
- 2023-01-24 JP JP2024543463A patent/JP2025503109A/ja active Pending
- 2023-01-24 IL IL314068A patent/IL314068A/en unknown
- 2023-01-24 WO PCT/EP2023/051721 patent/WO2023139293A1/en not_active Ceased
- 2023-01-24 EP EP23705485.3A patent/EP4469163A1/en active Pending
- 2023-01-24 CA CA3248133A patent/CA3248133A1/en active Pending
- 2023-01-24 US US18/158,980 patent/US20230295348A1/en active Pending
- 2023-01-24 CN CN202380018600.8A patent/CN118715024A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025503109A5 (enExample) | ||
| JP2021516974A5 (enExample) | ||
| JP2021533726A5 (enExample) | ||
| JP2020036595A5 (enExample) | ||
| JP2021515566A5 (enExample) | ||
| JP2021516973A5 (enExample) | ||
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| JP2015163068A5 (enExample) | ||
| JP2022515611A5 (enExample) | ||
| JP2020507328A5 (enExample) | ||
| JP2019535250A5 (enExample) | ||
| JP2020516654A5 (enExample) | ||
| JP2018531914A5 (enExample) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2017532037A5 (enExample) | ||
| JP2023528235A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| JP2022552090A (ja) | Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ | |
| JP2008543339A5 (enExample) | ||
| JP2023534847A5 (enExample) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JP2020507577A5 (enExample) | ||
| JP2018521959A5 (enExample) | ||
| Sadeghalvad et al. | Introduction on monoclonal antibodies | |
| JP2021522303A5 (enExample) |